Activity Overview
This educational activity is an archive of the live presentation held on May 30, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This
educational activity is directed toward oncologists, NPs/PAs, nurses,
pharmacists, and other HCPs involved in the management of breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement best practices for molecular testing in HR+/HER2-negative metastatic breast cancer, including selection of tissue vs liquid biopsy and indications for repeat testing at progression.
- Differentiate between available and emerging oral SERDs based on pivotal trial data, real-world evidence, and patient-specific factors to guide treatment selection in ESR1-mutant disease.
- Evaluate the role of oral SERD monotherapy versus combination regimens in the post-CDK4/6 inhibitor setting, balancing efficacy with tolerability.
- Develop individualized treatment strategies for patients with co-occurring ESR1 and PIK3CA mutations, integrating evidence for oral SERDs and PI3K/AKT pathway inhibitors.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
